Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry.

Lux MP, Nabieva N, Hartkopf AD, Huober J, Volz B, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Schneeweiss A, Brucker SY.

Cancers (Basel). 2018 Dec 21;11(1). pii: E10. doi: 10.3390/cancers11010010.

2.

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.

Fietz T, Lück A, Schulz H, Harde J, Losem C, Grebhardt S, Wolff T, Potthoff K, Müller U, Zaiss M, Kurbacher CM.

Curr Med Res Opin. 2018 Dec 17:1-12. doi: 10.1080/03007995.2018.1560200. [Epub ahead of print]

PMID:
30557099
3.

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial.

Hadji P, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Janni W, Muth M, Kreuzeder J, Quiering C, Grischke EM, Tesch H.

J Bone Oncol. 2018 Oct 2;14:010-10. doi: 10.1016/j.jbo.2018.09.010. eCollection 2019 Feb.

4.

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.

Tesch H, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Hadji P, Janni W, Muth M, Kreuzeder J, Quiering C, Taran FA.

Int J Cancer. 2019 Feb 15;144(4):877-885. doi: 10.1002/ijc.31738. Epub 2018 Oct 30.

PMID:
29992557
5.

Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.

Hartkopf AD, Huober J, Volz B, Nabieva N, Taran FA, Schwitulla J, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lux MP, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A.

Breast. 2018 Feb;37:42-51. doi: 10.1016/j.breast.2017.10.002. Epub 2017 Oct 26.

PMID:
29100043
6.

Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.

Möbus V, Jackisch C, Lück HJ, du Bois A, Thomssen C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Konecny GE, Untch M, Kurbacher C; AGO Breast Study Group (AGO-B).

Ann Oncol. 2018 Jan 1;29(1):178-185. doi: 10.1093/annonc/mdx690.

PMID:
29069370
7.
8.

Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.

Kurbacher CM, Horn O, Kurbacher JA, Herz S, Kurbacher AT, Hildenbrand R, Bollmann R.

Oncologist. 2015 Nov;20(11):1333-41. doi: 10.1634/theoncologist.2015-0076. Epub 2015 Sep 28.

9.

Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.

Kern P, Kalisch A, von Minckwitz G, Pütter C, Kolberg HC, Pott D, Kurbacher C, Rezai M, Kimmig R.

J Chemother. 2016 Jun;28(3):210-7. doi: 10.1179/1973947815Y.0000000061. Epub 2016 May 27.

PMID:
26239282
10.

NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis.

Kurbacher CM, Fietz T, Diel IJ, Egert M, Hurtz HJ, Lück A, Weide R, Salat C, Wolff T, Zaiss M, Klare P, Losem C, Illmer T, Weißenborn G, Steffens CC, Schulze M, Tesch H, Oskay-Oezcelik G, Teichmann B, Harde J, Scheuerlein RW.

Oncol Res Treat. 2015;38(5):221-9. doi: 10.1159/000381631. Epub 2015 May 4.

11.

Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response.

Kern P, Kalisch A, Kolberg HC, Kimmig R, Otterbach F, von Minckwitz G, Sikov WM, Pott D, Kurbacher C.

Chemotherapy. 2013;59(5):387-94. doi: 10.1159/000362756. Epub 2014 May 13.

12.

Response.

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz UA, Runnebaum IB, Hinke A, Kreienberg R, Untch M; AGO Breast Study Group.

J Natl Cancer Inst. 2014 Mar;106(3):djt452. doi: 10.1093/jnci/djt452. Epub 2014 Feb 28. No abstract available.

PMID:
24586093
13.

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; AGO Breast Study Group.

J Natl Cancer Inst. 2013 Jul 17;105(14):1018-26. doi: 10.1093/jnci/djt145. Epub 2013 Jul 16.

14.
15.

Isolation and culture of ovarian cancer cells and cell lines.

Kurbacher CM, Korn C, Dexel S, Schween U, Kurbacher JA, Reichelt R, Arenz PN.

Methods Mol Biol. 2011;731:161-80. doi: 10.1007/978-1-61779-080-5_15.

PMID:
21516407
16.

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M.

J Clin Oncol. 2010 Jun 10;28(17):2874-80. doi: 10.1200/JCO.2009.24.7643. Epub 2010 May 10.

PMID:
20458045
17.

Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.

Knight LA, Kurbacher CM, Glaysher S, Fernando A, Reichelt R, Dexel S, Reinhold U, Cree IA.

BMC Cancer. 2009 Jan 28;9:38. doi: 10.1186/1471-2407-9-38.

18.

Circulating 25-hydroxyvitamin D concentration in German cancer patients.

Reinhold U, Schmitz B, Kurbacher C, Nagel W, Schmidt M, Malaisse WJ.

Oncol Rep. 2008 Dec;20(6):1539-43.

PMID:
19020739
19.

A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.

Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S; TCA Ovarian Cancer Trial Group.

Anticancer Drugs. 2007 Oct;18(9):1093-101.

PMID:
17704660
20.

Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.

Hunz M, Jetter A, Warm M, Pantke E, Tuscher M, Hempel G, Jaehde U, Untch M, Kurbacher C, Fuhr U.

Clin Pharmacol Ther. 2007 May;81(5):659-68. Epub 2007 Feb 14.

PMID:
17301739
21.

Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.

Hille S, Rein DT, Riffelmann M, Neumann R, Sartorius J, Pfützner A, Kurbacher CM, Schöndorf T, Breidenbach M.

Anticancer Drugs. 2006 Oct;17(9):1041-4.

PMID:
17001177
22.

Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.

Knight LA, Conroy M, Fernando A, Polak M, Kurbacher CM, Cree IA.

Anticancer Drugs. 2005 Oct;16(9):969-76.

PMID:
16162973
23.

Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma.

Kurbacher CM, Kurbacher JA, Cramer EM, Rhiem K, Mallman PK, Reichelt R, Reinhold U, Stier U, Cree IA.

Oncology (Williston Park). 2005 Apr;19(4 Suppl 2):23-6.

24.

Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements.

Kurbacher CM, Cree IA.

Methods Mol Med. 2005;110:101-20. Review.

PMID:
15901931
25.

Treosulfan and gemcitabine.

Cree IA, Neale MH, Reinhold U, Kurbacher CM.

J Cancer Res Clin Oncol. 2005 May;131(5):329-30; author reply 331. Epub 2005 Feb 8. No abstract available.

PMID:
15700153
26.

Dysregulation of protein kinase C activity in chemoresistant metastatic breast cancer cells.

Schöndorf T, Hoopmann M, Breidenbach M, Rein DT, Göhring UJ, Becker M, Mallmann P, Kurbacher CM.

Anticancer Drugs. 2004 Mar;15(3):265-8.

PMID:
15014360
27.

Chemopersistent early recurrence in the perineal tear scar of an intrapartally diagnosed cervical cancer.

Hoopmann M, Valter M, Kurbacher C, Possover M, Mallmann PK.

Gynecol Oncol. 2003 Oct;91(1):272-4.

PMID:
14529694
28.

Preeclamptic women are deficient of interleukin-10 as assessed by cytokine release of trophoblast cells in vitro.

Rein DT, Breidenbach M, Hönscheid B, Friebe-Hoffmann U, Engel H, Göhring UJ, Uekermann L, Kurbacher CM, Schöndorf T.

Cytokine. 2003 Aug 21-Sep 7;23(4-5):119-25.

PMID:
12967647
29.

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.

Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Higgins BR, Lamont A, Osborne R, Hindley AC, Kurbacher CM, Cree IA.

BMC Cancer. 2003 Jul 3;3:19.

30.

Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer.

Breidenbach M, Rein DT, Schöndorf T, Schmidt T, König E, Valter M, Kurbacher CM.

Anticancer Drugs. 2003 Jun;14(5):341-6.

PMID:
12782939
31.

ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.

Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janát MM, Untch M, Konecny G, Bruckner HW, Cree IA.

Recent Results Cancer Res. 2003;161:221-30. Review.

PMID:
12528810
32.

Chemosensitivity testing in gynecologic oncology--dream or reality?

Untch M, Ditsch N, Langer E, Kurbacher C, Crohns C, Konecny G, Kahlert S, Bauerfeind I, Hepp H.

Recent Results Cancer Res. 2003;161:146-58. Review.

PMID:
12528806
33.

Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines.

Schöndorf T, Neumann R, Benz C, Becker M, Riffelmann M, Göhring UJ, Sartorius J, von König CH, Breidenbach M, Valter MM, Hoopmann M, Di Nicolantonio F, Kurbacher CM.

Recent Results Cancer Res. 2003;161:111-6.

PMID:
12528803
34.

Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study.

Rein DT, Kurbacher CM, Breidenbach M, Schöndorf T, Schmidt T, König E, Göhring UJ, Blohmer JU, Mallmann P.

Gynecol Oncol. 2002 Oct;87(1):98-103.

PMID:
12468349
35.

A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer.

König E, Kurbacher C, Schwonzen M, Breidenbach M, Mallmann P.

Anticancer Drugs. 2002 Sep;13(8):827-32.

PMID:
12394267
36.

Chemosensitivity of normal human trophoblasts evaluated by a newly developed ATP-based luminescence assay.

Kurbacher CM, Kurbacher JA, Cree IA, Wardelmann E, Stier U, Kolhagen H, Scharl A, Andreotti PE.

Anticancer Drugs. 2002 Aug;13(7):701-8.

PMID:
12187326
37.

Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines.

Schöndorf T, Kurbacher CM, Göhring UJ, Benz C, Becker M, Sartorius J, Kolhagen H, Mallman P, Neumann R.

Anticancer Res. 2002 Jul-Aug;22(4):2199-203.

PMID:
12174904
38.

Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer.

Di Nicolantonio F, Neale MH, Knight LA, Lamont A, Skailes GE, Osborne RJ, Allerton R, Kurbacher CM, Cree IA.

Anticancer Drugs. 2002 Jul;13(6):625-30.

PMID:
12172508
39.

Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment.

Breidenbach M, Rein DT, Mallmann P, Kurbacher CM.

Anticancer Drugs. 2002 Feb;13(2):173-6.

PMID:
11901311
40.

Cytokine expression in peripheral blood lymphocytes indicates a switch to T(HELPER) cells in patients with preeclampsia.

Rein DT, Schondorf T, Gohring UJ, Kurbacher CM, Pinto I, Breidenbach M, Mallmann P, Kolhagen H, Engel H.

J Reprod Immunol. 2002 Mar;54(1-2):133-42.

PMID:
11839400
41.

Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma.

Neale MH, Myatt NE, Khoury GG, Weaver P, Lamont A, Hungerford JL, Kurbacher CM, Hall P, Corrie PG, Cree IA.

Melanoma Res. 2001 Dec;11(6):601-9.

PMID:
11725206
42.

Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN.

Schöndorf T, Becker M, Göhring UJ, Wappenschmidt B, Kolhagen H, Kurbacher CM.

Anticancer Drugs. 2001 Nov;12(10):797-800.

PMID:
11707646
43.

The role of chemotherapy in invasive cancer of the cervix uteri: current standards and future prospects.

Rein DT, Kurbacher CM.

Anticancer Drugs. 2001 Nov;12(10):787-95. Review.

PMID:
11707645
44.

Heterogeneity of proteinkinase C activity and PKC-zeta expression in clinical breast carcinomas.

Schöndorf T, Kurbacher CM, Becker M, Warm M, Kolhagen H, Göhring UJ.

Clin Exp Med. 2001 Mar;1(1):1-8.

PMID:
11467396
45.

Prognostic value of repeated serum CA 125 measurements in first trimester pregnancy.

Schmidt T, Rein DT, Foth D, Eibach HW, Kurbacher CM, Mallmann P, Römer T.

Eur J Obstet Gynecol Reprod Biol. 2001 Aug;97(2):168-73.

PMID:
11451543
47.

Ex vivo assays to evaluate the role of protein kinase C in tumor cells of patients with breast cancer.

Schöndorf T, Becker M, Kolhagen H, Kurbacher CM, Göhring UJ.

Anticancer Res. 2000 Nov-Dec;20(6D):5073-6.

PMID:
11326671
48.

Lack of correlation between P53 expression, BCL-2 expression, apoptosis and ex vivo chemosensitivity in advanced human breast cancer.

Rein DT, Schöndorf T, Breidenbach M, Janát MM, Weikelt A, Göhring UJ, Becker M, Mallmann P, Kurbacher CM.

Anticancer Res. 2000 Nov-Dec;20(6D):5069-72.

PMID:
11326670
49.

The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma.

Neale MH, Lamont A, Hindley A, Kurbacher CM, Cree IA.

Anticancer Drugs. 2000 Nov;11(10):865-71.

PMID:
11142695
50.

Supplemental Content

Loading ...
Support Center